PMID- 30424591
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2383-7837 (Print)
IS  - 2383-7845 (Electronic)
IS  - 2383-7837 (Linking)
VI  - 53
IP  - 2
DP  - 2019 Mar
TI  - Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor 
      Prognosis in Patients with Advanced Breast Cancer.
PG  - 75-85
LID - 10.4132/jptm.2018.10.11 [doi]
AB  - BACKGROUND: Human leukocyte antigen class I (HLA-I) molecules play important 
      roles in regulating immune responses. Loss or reduction of HLA-I expression has 
      been shown to be associated with prognosis in several cancers. Regulatory T-cells 
      (Tregs) also play critical functions in immune response regulation. Evaluation of 
      HLA-I expression status by the EMR8-5 antibody and its clinical impact in breast 
      cancer have not been well studied, and its relationship with Tregs remains 
      unclear. METHODS: We evaluated HLA-I expression and Treg infiltration by 
      immunohistochemistry in 465 surgically resected breast cancer samples. We 
      examined the correlation between HLA-I expression and Treg infiltration and 
      clinicopathologic characteristics and survival analyses were performed. RESULTS: 
      Total loss of HLA-I expression was found in 84 breast cancer samples (18.1%). 
      Univariate survival analysis revealed that loss of HLA-I expression was 
      significantly associated with worse disease-specific survival (DSS) (p = .029). 
      HLA-I was not an independent prognostic factor in the entire patient group, but 
      it was an adverse independent prognostic factor for DSS in patients with advanced 
      disease (stage II-IV) (p = .031). Treg numbers were significantly higher in the 
      intratumoral stroma of HLA-I-positive tumors than in HLA-I-negative tumors 
      (median 6.3 cells/high power field vs 2.1 cells/high power field, p < .001). 
      However, Tregs were not an independent prognostic factor in our cohort. 
      CONCLUSIONS: Our findings suggest that the loss of HLA-I expression is associated 
      with poor prognosis in breast cancer patients, highlighting the role of HLA-I 
      alterations in immune evasion mechanisms of breast cancer. HLA-I could be a 
      promising marker that enables the application of more effective and precise 
      immunotherapies for patients with advanced breast cancer.
FAU - Park, Hong Sik
AU  - Park HS
AD  - Department of Hospital Pathology, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Korea.
FAU - Cho, Uiju
AU  - Cho U
AD  - Department of Hospital Pathology, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Korea.
FAU - Im, So Young
AU  - Im SY
AD  - Department of Hospital Pathology, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Korea.
FAU - Yoo, Chang Young
AU  - Yoo CY
AD  - Department of Hospital Pathology, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Korea.
FAU - Jung, Ji Han
AU  - Jung JH
AD  - Department of Hospital Pathology, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Korea.
FAU - Suh, Young Jin
AU  - Suh YJ
AD  - Department of Surgery, St. Vincent's Hospital, College of Medicine, The Catholic 
      University of Korea, Seoul, Korea.
FAU - Choi, Hyun Joo
AU  - Choi HJ
AD  - Department of Hospital Pathology, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Korea.
LA  - eng
GR  - SVHR-2016-13/St. Vincent's Hospital Research Institute of Medical Science 
      Foundation/
PT  - Journal Article
DEP - 20181114
PL  - Korea (South)
TA  - J Pathol Transl Med
JT  - Journal of pathology and translational medicine
JID - 101650151
PMC - PMC6435992
OTO - NOTNLM
OT  - Breast neoplasms
OT  - HLA antigens
OT  - Lymphocytes, tumor-infiltrating
OT  - Major histocompatibility complex
OT  - T-lymphocytes, regulatory
COIS- Conflicts of Interest The authors declare that they have no potential conflicts 
      of interest.
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:01
PMCR- 2019/03/01
CRDT- 2018/11/15 06:00
PHST- 2018/08/09 00:00 [received]
PHST- 2018/10/11 00:00 [accepted]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:01 [medline]
PHST- 2018/11/15 06:00 [entrez]
PHST- 2019/03/01 00:00 [pmc-release]
AID - jptm.2018.10.11 [pii]
AID - jptm-2018-10-11 [pii]
AID - 10.4132/jptm.2018.10.11 [doi]
PST - ppublish
SO  - J Pathol Transl Med. 2019 Mar;53(2):75-85. doi: 10.4132/jptm.2018.10.11. Epub 
      2018 Nov 14.